320 related articles for article (PubMed ID: 35878507)
1. Heterologous booster COVID-19 vaccination elicited potent immune responses in HCWs.
Saltoğlu N; Dinç HÖ; Balkan İİ; Can G; Özbey D; Beytur AN; Keskin E; Budak B; Aydoğan O; Mete B; Karaali R; Ergin S; Kocazeybek B
Diagn Microbiol Infect Dis; 2022 Oct; 104(2):115758. PubMed ID: 35878507
[TBL] [Abstract][Full Text] [Related]
2. SARS-CoV-2 specific antibody responses in healthcare workers after a third booster dose of CoronaVac or BNT162b2 vaccine.
Yavuz E; Günal Ö; Başbulut E; Şen A
J Med Virol; 2022 Aug; 94(8):3768-3775. PubMed ID: 35434796
[TBL] [Abstract][Full Text] [Related]
3. Dynamic of anti-spike receptor binding domain (RBD) levels and short-term adverse events following a heterologous booster dose of BNT162b2 after two doses of CoronaVac in Thai health care workers.
Kitro A; Sirikul W; Thongkum W; Soponpong S; Yasamut U; Kiratipaisarl W; Kosai A; Kasinrerk W; Tayapiwatana C; Srithanaviboonchai K
Vaccine; 2022 May; 40(21):2915-2924. PubMed ID: 35430106
[TBL] [Abstract][Full Text] [Related]
4. Comparison of humoral immune response in heterologous and homologous COVID-19 booster vaccine groups using CoronaVac and mRNA-based BNT162b2 vaccines.
Atıcı S; Soysal A; Gönüllü E; Aydemir G; Öner N; Alan S; Engin H; Yıldız M; Karaböcüoğlu M
Rev Soc Bras Med Trop; 2023; 56():e00462023. PubMed ID: 37493731
[TBL] [Abstract][Full Text] [Related]
5. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
Front Immunol; 2022; 13():863554. PubMed ID: 35711445
[TBL] [Abstract][Full Text] [Related]
6. Durability of anti-spike antibodies after vaccination with mRNA SARS-CoV-2 vaccine is longer in subjects with previous infection: could the booster dose be delayed?
Stellini R; Gianello R; Gomarasca W
Infection; 2022 Dec; 50(6):1573-1577. PubMed ID: 35391649
[TBL] [Abstract][Full Text] [Related]
7. Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study.
Barin B; Kasap U; Selçuk F; Volkan E; Uluçkan Ö
Lancet Microbe; 2022 Apr; 3(4):e274-e283. PubMed ID: 35165669
[TBL] [Abstract][Full Text] [Related]
8. Serological study of CoronaVac vaccine and booster doses in Chile: immunogenicity and persistence of anti-SARS-CoV-2 spike antibodies.
Vargas L; Valdivieso N; Tempio F; Simon V; Sauma D; Valenzuela L; Beltrán C; Castillo-Delgado L; Contreras-Benavides X; Acevedo ML; Acevedo J; Gonzalez RI; Valiente-Echeverría F; Soto-Rifo R; Rosemblatt M; Lopez M; Osorio F; Bono MR
BMC Med; 2022 Jun; 20(1):216. PubMed ID: 35676738
[TBL] [Abstract][Full Text] [Related]
9. Immunological responses and adverse reactions of the heterologous second booster dose of BNT162b2 after two-dose CoronaVac for COVID-19 vaccination in healthcare workers of Faculty of Medicine, Naresuan University.
Makanut S; Wangteeraprasert A; Jitpewngam W; Ngoenkam J; Pongcharoen S
Vaccine; 2023 Jun; 41(29):4335-4340. PubMed ID: 37301707
[TBL] [Abstract][Full Text] [Related]
10. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
Costa Clemens SA; Weckx L; Clemens R; Almeida Mendes AV; Ramos Souza A; Silveira MBV; da Guarda SNF; de Nobrega MM; de Moraes Pinto MI; Gonzalez IGS; Salvador N; Franco MM; de Avila Mendonça RN; Queiroz Oliveira IS; de Freitas Souza BS; Fraga M; Aley P; Bibi S; Cantrell L; Dejnirattisai W; Liu X; Mongkolsapaya J; Supasa P; Screaton GR; Lambe T; Voysey M; Pollard AJ;
Lancet; 2022 Feb; 399(10324):521-529. PubMed ID: 35074136
[TBL] [Abstract][Full Text] [Related]
11. Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination.
Pérez-Then E; Lucas C; Monteiro VS; Miric M; Brache V; Cochon L; Vogels CBF; Malik AA; De la Cruz E; Jorge A; De Los Santos M; Leon P; Breban MI; Billig K; Yildirim I; Pearson C; Downing R; Gagnon E; Muyombwe A; Razeq J; Campbell M; Ko AI; Omer SB; Grubaugh ND; Vermund SH; Iwasaki A
Nat Med; 2022 Mar; 28(3):481-485. PubMed ID: 35051990
[TBL] [Abstract][Full Text] [Related]
12. Antibody response after a third dose mRNA-1273 vaccine among vaccinated healthcare workers with two doses of inactivated SARS-CoV-2 vaccine.
Cucunawangsih C; Wijaya RS; Lugito NPH; Suriapranata I
Int J Infect Dis; 2022 May; 118():116-118. PubMed ID: 35192955
[TBL] [Abstract][Full Text] [Related]
13. COVID-19 lateral flow IgG seropositivity and serum neutralising antibody responses after primary and booster vaccinations in Chile: a cross-sectional study.
Sauré D; O'Ryan M; Torres JP; Zuñiga M; Soto-Rifo R; Valiente-Echeverría F; Gaete-Argel A; Neira I; Saavedra V; Acevedo ML; Archila C; Acuña F; Rain M; Basso LJ
Lancet Microbe; 2023 Mar; 4(3):e149-e158. PubMed ID: 36716754
[TBL] [Abstract][Full Text] [Related]
14. [The Second Shot of CoronaVac Vaccine May Cause Reduction of Antibody Levels in People who Previously had COVID-19].
Topkaya AE; Keskin AÜ; Dalan AB; Çıragil P
Mikrobiyol Bul; 2022 Jan; 56(1):139-142. PubMed ID: 35088968
[TBL] [Abstract][Full Text] [Related]
15. An analysis of antibody response following the second dose of CoronaVac and humoral response after booster dose with BNT162b2 or CoronaVac among healthcare workers in Turkey.
Çağlayan D; Süner AF; Şiyve N; Güzel I; Irmak Ç; Işik E; Appak Ö; Çelik M; Öztürk G; Alp Çavuş S; Ergör G; Sayiner A; Ergör A; Demiral Y; Kiliç B
J Med Virol; 2022 May; 94(5):2212-2221. PubMed ID: 35075655
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity, Effectiveness, and Safety of Inactivated Virus (CoronaVac) Vaccine in a Two-Dose Primary Protocol and BNT162b2 Heterologous Booster in Brazil (Immunita-001): A One Year Period Follow Up Phase 4 Study.
Grenfell RFQ; Almeida NBF; Filgueiras PS; Corsini CA; Gomes SVC; de Miranda DAP; Lourenço AJ; Martins-Filho OA; de Oliveira JG; Teixeira-Carvalho A; Campos GRF; Nogueira ML; Alves PA; Fernandes GR; Castilho LR; Lima TM; de Abreu DPB; Alvim RGF; Silva TBS; Jeremias WJ; Otta DA; Campi-Azevedo AC;
Front Immunol; 2022; 13():918896. PubMed ID: 35757764
[TBL] [Abstract][Full Text] [Related]
17. Antibody Response to SARS-CoV-2 Vaccines in People with Severe Obesity.
Kara Z; Akçin R; Demir AN; Dinç HÖ; Taşkın HE; Kocazeybek B; Yumuk VD
Obes Surg; 2022 Sep; 32(9):2987-2993. PubMed ID: 35802279
[TBL] [Abstract][Full Text] [Related]
18. Neutralizing antibody responses elicited by SARS-CoV-2 mRNA vaccination wane over time and are boosted by breakthrough infection.
Evans JP; Zeng C; Carlin C; Lozanski G; Saif LJ; Oltz EM; Gumina RJ; Liu SL
Sci Transl Med; 2022 Mar; 14(637):eabn8057. PubMed ID: 35166573
[TBL] [Abstract][Full Text] [Related]
19. T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a multicentre prospective cohort study.
Angyal A; Longet S; Moore SC; Payne RP; Harding A; Tipton T; Rongkard P; Ali M; Hering LM; Meardon N; Austin J; Brown R; Skelly D; Gillson N; Dobson SL; Cross A; Sandhar G; Kilby JA; Tyerman JK; Nicols AR; Spegarova JS; Mehta H; Hornsby H; Whitham R; Conlon CP; Jeffery K; Goulder P; Frater J; Dold C; Pace M; Ogbe A; Brown H; Ansari MA; Adland E; Brown A; Chand M; Shields A; Matthews PC; Hopkins S; Hall V; James W; Rowland-Jones SL; Klenerman P; Dunachie S; Richter A; Duncan CJA; Barnes E; Carroll M; Turtle L; de Silva TI;
Lancet Microbe; 2022 Jan; 3(1):e21-e31. PubMed ID: 34778853
[TBL] [Abstract][Full Text] [Related]
20. Humoral immune response characterization of heterologous prime-boost vaccination with CoronaVac and BNT162b2.
Rammauro F; Carrión F; Olivero-Deibe N; Fló M; Ferreira A; Pritsch O; Bianchi S
Vaccine; 2022 Aug; 40(35):5189-5196. PubMed ID: 35907676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
